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INTRODUCTION 
 
DIABETES MELLITUS: 
Diabetes mellitus (DM) is a major public health problem worldwide.  
According to WHO, India will be a world diabetic capital in 2025. (1)  
Diabetes mellitus (DM) is a metabolic syndrome, which affects multiple 
organ systems in the body. There is a drastic increase in the incidence and 
prevalence of DM in Asian Indians. (1)  
In India the total number of people suffering from diabetes would be 
around 87 million in 2030 according to an estimate by International Diabetes 
Federation(IDF).(2)  
  In diabetes mellitus (DM) is there occurs disturbance of carbohydrate, 
protein and fat metabolism. DM is due to defect in insulin secretion, insulin action 
or both which is characterized by chronic hyperglycemia. (3) 
The major risk factors for developing diabetes are increasing age, 
physically inactive lifestyle and obesity. 
  Obesity predisposes to insulin resistance. Circulating levels of insulin may 
be normal or increased in such people yet inadequate to control blood glucose 
levels due to insulin resistance. Their glycemic status can be brought to control by 
weight reduction and anti-glycemic drugs as insulin resistance can be improved 
with weight reduction. (3) 
A diabetic patient may have symptoms like visual blurring, polydipsia, 
polyuria, polyphagia. The patient may also present with marked weight loss. In 
severe uncontrolled diabetes the patient can go in for diabetic ketoacidosis. 
Negligence, improper drug intake by the patient or lack of effective treatment will 
ultimately end up in diabetic coma and death. 
 CLASSIFICATION OF DIABETES MELLITUS: 
Diabetes can be broadly classified into type I and type II. 
Type I diabetes is due to destruction of β-cell which leads to deficiency of 
insulin. Type II results from insulin resistance with relative insulin         
deficiency.(4, 5) 
Type II diabetes is more common. A person diagnosed with type II 
diabetes will have disorders of insulin action and insulin secretion. There occurs 
progressive destruction of β-cells as disease duration increases (6) 
Type-II DM does not produce classic symptoms as hyperglycemia. It 
develops only gradually and hence difficult to diagnose in the early stage itself. 
Diabetes is often diagnosed as a result of routine blood or urine investigations. 
Therefore, by the time a person is diagnosed to be diabetic, would have developed 
many functional as well as pathologic changes in the body.  
Long term effects of diabetes include failure and dysfunction of various 
organs which includes blood vessels, kidneys, heart and eyes. Patients are at high 
risk for developing microvascular and macrovascular complications.      
Micro-macro vascular pathologies can have detrimental effects on many 
organs. The various micro vascular complications such as retinopathy, 
nephropathy and neuropathy are well documented. However, the lung disorders 
that occur due to diabetes have poor documentations with variable results. (7)  
The involvement of lung remains asymptomatic until late stages of the 
disease. The scleroproteins collagen and elastin, which forms the major tissue 
proteins in bronchi, pulmonary vessels and interstium, are altered due to 
hyperglycemia there by affecting the pulmonary functions. 
In normoglycemic individuals there occurs enzymatic glycosylation of 
proteins, which is essential for the proteins to become functionally active. 
Enzymatic glycosyltion is actually a part of post-translational modification of 
proteins, which is catalysed by enzymes. In some cases, this process is essential 
for the proteins to function as enzymes. 
Thus in this process there occurs addition of sugar or saccharide derivative 
to the protein, in the presence of an enzyme. Whereas, in hyperglycemic 
individuals there occurs non-enzymatic glycosylation of proteins. 
Non-enzymatic glycosylation in other terms is called as glycation. Here 
there is addition of sugar to protein in the absence of enzymes. Once the protein 
becomes glycated, its function markedly reduces. Thus enzyme activity of these 
proteins are reduced. The end-products of glycation are called as advanced 
glycation end products (AGEs). These products on long term basis gets deposited 
in the tissues especially collagen, elastin and lens crystallins. Once deposited, then 
this process becomes irreversible. These proteins then cannot fold upon 
themselves and they lose their normal functions. And their normal turnover is 
dropped and they can’t be properly recycled. This can lead to too many pathologic 
processes, which ultimately ends up in diseases. (8)  
Non- enzymatic glycosylation (glycation) of elastin and collagen leads to 
thickening of basement membrane and microangiopathy which in turn may 
restrict lung volumes and capacities leading to development of restrictive pattern 
of lung disease. (1) This can potentially incapacitate the patients and further worsen 
their quality of life. Hence assessing the pulmonary status of these patients at the 
outset is essential in retarding the progression of the disease, its management and 
prognostication.  
These alterations can be delayed by maintaining blood sugar within normal 
range. These changes can also be seen as age advances but progression and 
intensity of changes are more pronounced in patients with diabetes          mellitus. 
(9)   
Pulmonary Function Tests (PFT) are widely used to provide a measure of 
lung function for assessing and quantifying pulmonary impairment in various 
clinical conditions and for monitoring response to therapy, effect of 
environmental, occupational and drug exposures-associated with lung diseases.  
 
 
SPIROMETRY: 
Spirometry is the most common and most useful lung function test that has 
extensive clinical implications. It is an easy test to perform and is widely available 
at hospitals.  Measurement of respiratory volumes and capacities is an essential 
tool for determining how well the lung is functioning. 
 Assessment of mechanics of lung and chest wall, lung volume and 
capacities will help to screen for any obstructive or restrictive lung 
pathologies.PFT also will help to document the progression of lung disease and 
effectiveness of any therapeutic intervention. 
Spirometry has static as well as dynamic components. 
Static – Includes lung volumes 
Dynamic – Includes time  
Subjects can be categorized to have normal pulmonary function or 
obstructive and restrictive lung pathologies based on the dynamic PFTs. 
Patients with an obstructive pattern as in conditions like asthma, bronchitis 
will have decreased air flow where the rate at which air can be expelled from the 
lungs is affected and this condition is characterized by decrease in FEV1 (forced 
expiratory volume at the end of first second) , normal FVC (forced vital capacity) 
and low FEV1 to FVC ratio. An FEV1/FVC ratio of ≤ 0.7 (70%) confirms 
obstructive pathology (10). 
In restrictive pattern of lung disease which occurs in conditions like 
kyphosis, scoliosis, lung fibrosis will affect the lung expansion which can result in 
reduced lung volumes or total lung capacity with a normal air flow. That is here 
FEV1 and FVC values are reduced with a normal FEV1 /FVC ratio. (11) 
 
The load- bearing elements also the structural proteins of the lung 
parenchyma that is the connective tissue components (collagen and elastin) 
undergo non-enzymatic cross- linking during aging and in diabetes.(12) 
 
In diabetic individuals non enzymatic glycation of these proteins will result 
in the formation of advanced glycated end-products that can lead to structural and 
functional changes in the collagen-elastin fibre network. This can affect the 
alveolar duct wall which in turn will affect the micromechanics of lung 
parenchyma i.e. the elastic recoiling of the lung will be affected that in turn will 
affect the rate at which the air is forced out. 
 
The effect of diabetes on lung functions was proved by a study conducted 
by Plopper et al. (13)  The study was done in rats. In this study, diabetes was  
induced in rats with the help of streptozotocin. Then on studying the histology of 
pulmonary tissue it was found that, there were changes in the structure of granular 
pneumocytes, scleroproteins present on the wall of the alveoli(14) and clara 
cells.(15) It was postulated that these changes could be due to the side effects of the 
drug itself. However, a study done by Kida et al. (14) showed that these were due to 
the deficiency of insulin.The adverse effect of diabetes on lung functions were 
demonstrated in the post-mortem studies done on the diabetic patients. It showed 
thickening of basement membrane of capillaries of alveoli, which suggested 
microangiopathy. (16) Microangiopathy was also reflected on the alveolar septal 
capillaries as well as on the alveolar and pleural arterioles. (17, 18)   
  
AIMS AND OBJECTIVES 
AIM: 
         To assess the pulmonary functions of diabetic patients.  
OBJECTIVES: 
        1. To assess and compare the pulmonary functions of diabetic patients  with 
age and BMI matched healthy individuals. 
        2. To correlate the lung functions of diabetic patients with their BMI (Body 
mass index) and HbA1c (glycosylated hemoglobin). 
JUSTIFICATION: 
 The pulmonary complications of Diabetes mellitus can have severe impact 
on the quality of life of the affected individuals. 
 The studies related to the effect of diabetes on pulmonary functions are 
relatively few and there is lack of adequate data on Indian population. 
 This study will focus on the pulmonary dysfunction, maximal forced 
spirometric pulmonary function tests to be specific.  
 
 
 
 
 
 
REVIEW OF LITERATURE 
There is an alarming increase in the incidence and prevalence of DM in 
Asian Indians. (1) In India the total number of people suffering from diabetes 
would be around 87 million in 2030 according to an estimate by International 
Diabetes Federation(IDF).(2) 
A report by WHO predicts that the prevalence of diabetes among adults 
around the world would increase up to 300 million in 2025. (1) 
Developing countries had an approximate of 84 million diabetics in the 
year 1995(19) .WHO suggests that in 2025 the percentage of diabetics would rise 
up to 57.2 million in India (1) So approximately 75% of the population is prone for 
diabetes in future. Urban areas have been reported to have high prevalence for 
DM (20) .It has increased from 2.1% in early 1970, to 11.6% in 1996(21). 
Though the rate of conversion of impaired glucose tolerance to full prone 
DM is low,  many people are subjected to the risk of developing the same. (22) 
Diabetes mellitus, a metabolic syndrome characterized by hyperglycemia 
occurs due to derangement in the metabolism of carbohydrate, protein and fat. (23) 
Classification of diabetes is now based on: 
1. Clinical stages 
2. Etiological types 
In 1997 the American Diabetes Association (ADA) proposed clinical 
classification of diabetes(4) Later in 1999 the World Health Organization (WHO) 
adopted this classification.(5) 
Clinical stages of diabetes: 
    1.  Stage of normal glucose tolerance 
    2. Stage of impaired glucose regulation (Impaired glucose tolerance/ 
Impaired fasting glucose). 
    3.   Stage of diabetes mellitus 
 Not insulin requiring 
 Insulin requiring for control 
 Insulin requiring for survival 
Etiological classification: 
1) Type1:   
Due to destruction of β-cell. This condition leads to absolute insulin 
deficiency. 
Causative factors: 
 Autoimmune conditions 
 Idiopathic 
 
 
2) Type 2:  
Due to insulin resistance. 
This condition is characterized by relative deficiency of insulin. 
Causative factor: 
Defect in secretion of insulin. This defect in secretion can be either with 
insulin resistance or without insulin resistance. 
 3)  Gestational diabetes 
  4)  Other types of diabetes: 
 β cell dysfunction due to genetic causes. 
 Defective action of insulin due to genetic defects. 
 Infections 
 Diseases of exocrine pancrease. 
 Endocrinopathies. 
 Immune mediated diabetes 
 Drug or chemical induced diabetes 
 Diabetes associated with genetic syndromes.  
Criteria for diagnosis of diabetes (24) 
1. Fasting plasma glucose    - ≥ 126 mg/dl or ≥ 7.0 mmol/L 
2. Two-hour plasma glucose - ≥ 200 mg/dl or ≥ 11.1 mmol/L 
3. HbA1c                             - ≥ 6.5 % 
Risk factors for diabetes (25) 
 Hereditary factors 
 Ethnicity 
 Positive history of previous gestational diabetes 
 Unhealthy dietary practices 
 Sedentary life style  
 Over weight, Obesity 
 Smoking 
The commonest risk factor for type 2 diabetes is excess weight gain owing 
to unhealthy dietary habits and physical inactivity. 
Physical inactivity together with overweight and obesity poses the greatest 
risk for the cause of global diabetes burden(26) But this association varies in 
different set of population.(27) Diabetes develops in South-East Asians at a lower 
range of BMI as when compared to Europeans.(28) 
Common diets that pose the risk of type 2 diabetes are: 
 High consumption of saturated fats 
 Excess intake of total fat 
 Less consumption of dietary fiber(29,30,31) 
 Beverages containing free sugars(32)  
 
The new WHO report is emphasizing the government to make sure that 
every individual is able to take up healthy choices and that the system of health 
care should be able to make the diagnosis, provide treatment and care for those 
with diabetes. It encourages every individual to eat healthy, be active, physically 
fit and prevent excessive weight gain. This was issued by WHO on world health 
day 2016, which made a call for effective action on diabetes in both prevention as 
well as treatment (33) 
OBESITY: 
Obesity is defined as weight about ≥ 20% of average weight per height 
(34).A body mass index of more than 30mg/kg2 is considered as obese. 
The different classes of BMI values which are used to categorize a person 
as obese or normal is calculated by the formula: 
                  Weight in kg / (Height in meter) (34) 
     BMI in kg/m2                           CATEGORY 
1.   < 18.5                                   Underweight 
2. 18.5 – 24.9                              Normal 
3. ≥ 25.0 – 29.9                           Overweight 
4. ≥ 30                                         Obese 
5. 30 – 39.9                                  Obese class 1 
6. 40 – 49.9                                   Obese class 2 
7. ≥ 50                                          Obese class 3    
OBESITY AND DIABETES: 
Obesity is known to cause a low grade inflammation. The chronic 
inflammatory process is characterized by rise in blood levels of pro-inflammatory 
cytokines gain an access through blood stream to cause systemic inflammation .(35) 
This can cause insulin resistance. 
A recent study showed that treatment with salicylate can cause 
improvement in insulin resistance. (35) Studies show that lifestyle changes and 
certain therapies that reduce obesity can prevent diabetes. (36) 
 
OBESITY AND LUNG FUNCTION: 
       Obesity can cause marked reduction in lung volumes and capacities. The 
mechanism behind reduction in lung functions is attributed to the fact that in 
obese individuals there is mechanical limitation to the abdominal and thoracic 
movements owing to increased fat deposition in these areas. This can cause 
reduction in the compliance of chest wall and air flow limitation leading to 
reduced lung function.(37) 
In obese individuals the increased abdominal obesity restricts the 
downward movement of the diaphragm. This limits the lung expansion thereby 
decreasing the total lung capacity. This is proved by the fact that weight reduction 
helps in increasing the total capacity. (38, 39) 
 
Fat deposition in sub-pleural spaces can possibly reduce the volume of 
chest cavity which in turn can affect the lung volumes.(40)Metabolic rate in obese 
individuals are high. Hence, there is an increase in consumption of oxygen and 
production of carbon dioxide. Thus, minute ventilation is increased in such 
individuals. As the compliance of the thoracic wall is decreased in these 
individuals, the work of breathing is increased and the respiratory reserve volume 
and vital capacity is reduced. (41) 
Thus due to alteration in the ventilation-perfusion ratio the person may 
develop hypoxia and hypercapnia leading to respiratory acidosis. 
As discussed earlier increase in prevalence of diabetes is attributed to 
following factors:(42) 
 Genetic predisposition 
 Unbalanced diet rich in carbohydrates and fats 
 Sedentary life style 
 Stress 
One of the common reason for stress and sedentary life style are fast 
urbanization.  A report by WHO states that the annual cost for diabetic care in 
2002 was Rs.12, 000 for those on insulin and Rs 2400 for those on oral 
hypoglycemic. So almost 75.2 billion is needed for a standard treatment for an 
estimate of 20% treated with insulin among the 17.3 million affected with 
diabetes in India. (12)  
 
A study conducted in The United States of America shows that about 6% of 
women and 11% of men who are diabetic and between 45 to 65 years are reported 
to have myocardial infarction. Compared to the non-diabetics the risk percentage 
for MI in diabetic men and women are 4 and 2.5 times higher respectively.   
 
There is high risk of atherosclerosis even in pre-diabetic individuals. Among 
the type -2 diabetics around half of middle aged men and women are found to 
have symptomatic CHD, the moment their disease is diagnosed (43). The 
development of atherosclerosis is gradual which results in hyperinsulinemia and 
hyperglycemia even before actual onset of type- II DM (44). 
 
Hyperglycemia is the main cause of non-enzymatic glycosylation of the 
scleroproteins. The study defines glycation as the formation of complexes 
between amino acids and sugars, which is the reason for browning and hardening 
of food on heating. 
 
 
  
MAILLARD REACTION / ADVANCED GLYCATION: 
 
The chemical reactions that results in non-enzymatic glycation of proteins 
by reducing sugars is known as Maillard reaction. 
Glycotoxins or advanced glycation end products(RAGEs) are formed as a 
result of cross reaction between amino acids and reducing sugars(45) which is the 
reason for different pathologies in diabetes. The presence of these moieties in vivo 
is unknown but tissues of diabetics show elevated levels of these moieties (46). 
Protein glycation can be reduced on administration of vitamin E.(47)The 
toxic moieties formed due to glycation contribute to the developing renal, 
neurological, vascular, and atherosclerotic changes in old age and diabetes. The 
accumulation of toxic products at the sites of neuronal degeneration has been 
observed in Alzheimer’s disease(48). 
Non-enzymatic glycation of proteins can lead to multi system disorders 
like: End stage renal disease, blindness, stroke, ischemic heart disease, 
neuropathy, peripheral vascular disease.(49) All these complications can be reduced 
by preventing the cross link formation between proteins and reducing sugars and 
also by preventing the accumulation toxic moieties that is advanced glycation 
products in the body. This can also be achieved by inhibiting the glycation 
products by blocking their receptors by means of certain drugs and this requires 
adequate knowledge about the various mechanisms underlying the pathogenesis 
of diabetes. Pyridoxamine and aminoguanidine are proved to prevent the 
formation of AGE’s in animal models(12). 
MECHANISM OF FORMATION OF ADVANCED GLYCATION 
PRODUCTS: 
A study by R B Nawale et al. suggests that high sugar levels is an 
important factor which can lead to glycation of lysine residue of protein which 
can affect their function. The process of advanced glycation is initiated when 
glucose reacts with amino acid residues of proteins to form certain 
moieties(50)which  results in the formation of Schiff bases that inturn are converted 
into Amadori products(51) . 
Amodari products undergo rearrangement and cross linkage to form 
advanced glycated end products (AGEs) that can alter the structure and function 
of proteins which is common in diabetes and aging. (52) These reactions take place 
at a slow rate so only proteins with long half-lives and those containing lysine 
residues eg. collagen undergo glycation. 
  when sugar levels are high the rate at which glycation takes place is 
markedly elevated and the renal clearance of these adverse moieties are decreased 
and the receptors for AGEs are increased , which can lead to age mediated cell 
activation and amyloidosis(53). 
DISTRIBUTION AND ROLE OF ELASTIN FIBERS IN LUNGS: 
The micromechanics of lungs are mainly attributed to the connective tissue 
network in the lung parenchyma. Connective tissue fibers are found on the 
alveolar duct wall in high concentration. 
A ring like structure which is continuous is formed around the mouth of 
each alveoli. The elastin fibres tend to pass deep into the septal wall of the alveoli.  
Elastin fibers are broadly distributed in tissues like lung parenchyma, 
pleura, certain ligaments and arteries. The elasticity of these fibers allows them to 
stretch and can cause elastic recoiling as and when required.(54) 
DISTRIBUTION AND ROLE OF COLLAGEN IN LUNGS: 
The structural integrity of the lung tissue is mainly dependent on the 
collagen fibers. Collagen especially type1 and type 2 is distributed widely in the 
interstitium of the lung. Collagen fibers also act as a connecting bridge between 
the visceral pleura and the alveolar ducts. Thus collagen plays an important role as 
a load bearing element of alveolar duct and wall.(55) Collagen and elastin fibres are 
found to be closely associated and connected to each other.(56)Thus collagen is 
found to play an equal and important role in lung elasticity.(57) 
Collagen helps in preventing over stretching of the lung matrix. The cross 
linking between the collagen fibers, number of fibrils and its diameter determines 
the stiffness of the collagen fibers that is enhanced cross linking and increased 
diameter of the collagen fibers have the tendency to increase the stiffness of 
normal collagen. (58, 59)Type 1 collagen is found to be stiffer than type 3 and both 
of them play an important role in fiber stiffness.  
 
 
ROLE OF INTERSTITIAL CELLS IN LUNG MECHANICS: 
The smooth muscle cells located in the alveolar ducts, walls of blood 
vessels as well as the myofibroblasts of the alveolar walls play important role as 
contractile cells.(60)The viscoelastic properties of lung can be moderately modified 
by the stress generated by the stimulation of these fibers.(61) But the main role of 
these cells are in the active repair of the connective tissue.(62) 
Surface tension forces acting on the lung tissues play an important role in 
micromechanics of lungs.(54)Surfactant produced by the type 2 pneumocytes lines 
the alveoli and airways which contributes to stability of alveoli and prevents it 
from collapse when the lung volume goes down.(63)Studies show that the quantity 
of surfactant produced and its composition depends on the pattern of stretching of 
the lung parenchyma.(64) 
LUNG AS A TARGET ORGAN IN DIABETES: 
The discussion shows that apart from other complications of diabetes such 
as retinopathy, nephropathy and neuropathy, lung also is a target organ in a person 
with long standing diabetes. The non-enzymatic glycosylation of the 
scleroproteins which are widely distributed in the chest wall and bronchial tree 
and enhanced cross link formation between the collagen fibers are attributed to the 
marked reduction in the mechanical function of lungs.(65)More over any change in 
the quality and quantity of collagen can lead to restrictive impairment in lung 
function.(66)As collagen is non enzymatically glycosylated in diabetic individuals 
they exhibit resistance to digestion by collagenase and pepsin as compared to 
normal non-diabetic healthy individuals.(67)Adding on to it, the reduction in the 
normal turnover of collagen fibers can lead to reduction in the compliance of the 
lung parenchyma. As compliance of lung decreases restrictive type of ventilatory 
defect develops in the diabetic lung.(68) The mechanical function of lungs which is 
determined by its elasticity can be tested by spirometric pulmonary function 
tests.(69) 
Restrictive pattern of lung function can be determined by low values of 
spirometric pulmonary function tests. (10) 
Lung volumes: 
1. Forced vital capacity (FVC) – It is the maximum volume of air that can be 
exhaled forcefully and rapidly with effort after a deep inhalation. The test 
becomes significant only if the person can exhale forcefully for six seconds or 
more. 
Normal value is 80-120% 
In diabetic individuals this value is reduced. This is attributed to increase in 
formation of cross linkage between polypeptides of collagen embedded in the 
connective tissue matrix of lung parenchyma. 
2. Forced expiratory volume at first second (FEV1) – It is the volume of air that is 
exhaled in the first second of maximal exhalation after a deep inspiration. 
This is a useful tool to assess, how rapidly the lungs can be emptied. 
Normal value is 80-120%. 
In diabetic individuals this value is also decreased. This is also attributed to the 
stiffening of the lung parenchyma due cross link formation between collagen 
fibers as a result of enhanced glycosylation of collagen fibers due to 
hyperglycemia. 
3. FEV1 / FVC: 
 The best index of airflow limitation can be given by the ratio of FEV1 to FVC.  
Normal value that is the absolute ratio should be within 5% of the predicted ratio. 
Here FEV1 is expressed in terms of percentage of FVC. 
In diabetic individuals with restrictive pattern of lung disease, this value is either 
normal or increased that is ≥ 70%. 
4. Peak expiratory flow rate (PEFR) – This flow rate is reached immediately by 
the first bout of air as the person exhales. This helps to assess the following 
parameters: 
 Helps to judge if the person is putting in maximum effort during the 
procedure. 
 Quality of the test 
 Strength of muscles of expiration 
 Condition of large airways 
In diabetic individuals due to modification of collagen and elastin ratio the 
mechanical properties of lungs are altered which reflects as reduced compliance 
and poor elastic recoil of lungs. All these factors will affect the peak expiratory 
flow rate. 
5. FEF25-75% : 
This shows the forced expiratory flow in the middle half of forced vital 
capacity that is the average flow from the point at which 25% of forced vital 
capacity has been breathed out to the point at which 75% of forced vital capacity 
has been breathed out. This indicates the patency of small airways. 
In a person who is diabetic for a long period the lung may be subjected to 
damage. This chronic status of lung disease will first be represented in the 
smallest airways and in the flow volume loop this early damage will reflect 
towards the end of the expiratory part of the loop. This may be due to poor elastic 
recoil forces and poor muscular support of the respiratory system which is 
essential for forced expiration.(70) 
Certain studies have shown that activity of the enzyme lysyl oxidase is 
increased in rats which developed diabetes that was experimentally induced. This 
enzyme is involved in connective tissue formation. Thus in diabetic individuals 
enhanced activity of these enzymes will lead to thickening of alveolar 
interstitium.(71) 
 
 
INVOLVEMENT OF RESPIRATORY MUSCLES AND 
NEUROMUUCULAR FACTORS IN DIABETES: 
Loss of force generating capacity of the muscles of expiration can result in 
reduction of peak expiratory flow rate along with poor elastic recoiling of 
lungs.(72,73) Similarly FEF25-75% is said to depend on both the neuromuscular 
factors as well as the mechanical properties of the respiratory system as  FEF25-
75% depicts nothing but the initial part of forced vital capacity.(74) 
These factors show that the muscles of respiration are involved in diabetes. 
This can be due to enhanced protein catabolism owing to high blood glucose 
level. This can ultimately lead to poor strength of skeletal muscles. (75) 
The defect in respiratory pump mechanism is also attributed to 
development of diabetic polyneuropathy. As glycosylation causes thickening of 
the basement membrane in almost all tissues, they can cause demyelination as 
well as chromatolysis of axon as well as Schwann cells apart from 
microangiopathy.(76)Thus it shows that thoracic nerves and phrenic nerve, which 
are predominant nerve supply for the muscles of respiration including diaphragm 
is affected in diabetic individuals.(76,77) 
ROLE OF OXIDATIVE STRESS IN LUNG DYSFUNCTION: 
High blood sugar level can lead to endothelial dysfunction. Increased blood 
sugar level can increase the endothelial cell production of free radicals. This can 
impede with the vessel dilatation.(78)This occurs due to oxidative stress. It is 
proved as this process can be reversed by treatment with antioxidants or L- 
arginine. 
The mechanism behind this is that, the free radical production due to high 
blood sugar results in the activation of protein kinase-C and nuclear factors. This 
results in formation of AGEs within the cells. (79) Hyperglycemia can lead to 
increase in production of superoxide anion. This leads to increase in the levels of 
superoxide than nitric oxide within the endothelial cells, which ultimately results 
in the production of nitrotyrosine and peroxinitrate. The major marker for 
oxidative stress is nitrotyrosine. In patients with endothelial dysfunction and in 
those with diabetes the nitrotyrosine level seems to be increased. (80,81)Thus it 
shows that oxidative stress can lead to endothelial dysfunction in diabetic 
subjects. 
This process can affect the respiratory apparatus in diabetic patients. The 
oxidative stress induced by hyperglycemia can lead to loss of integrity of 
pulmonary capillary endothelium, which in turn can affect the gas exchange 
process across the respiratory membrane. This can also affect the blood volume in 
the lung capillaries, as acute increase in blood sugar can suppress vasodilatation 
due to oxidative stress.(69) 
  Similarly markers of inflammation in the epithelial lining fluid of lungs can 
be assessed by measuring the markers of inflammation in the exhaled breath 
condensate. It was found that the concentration of leukotrine B4 was increased 
four times in patients with chronic obstructive pulmonary disease with diabetes 
than those without diabetes.(82) Studies suggests that oxidative stress induced by 
high blood sugar level is attributed to non-enzymatic glycosylation of proteins 
along with low plasma levels of ascorbate. The ideal measure for oxidative stress 
is urinary F2 isoprostanes. This was found to be increased in diabetic subjects. 
But studies have shown that supplementing these people with α-tocopherol tends 
to decrease the levels of isoprastanes in urine.(78)Another study shows that 1250 
mg of vitamin c, 680 units of α-tocopheral given for four weeks daily resulted in 
reduction in albuminuria.(83)Another study showed that treating type1 diabetic 
subjects with 1800 units of α-tocopheral for four months daily showed 
improvement in blood flow to retina and creatinin clearance.(84) 
GLYCOSYLATED HEMOGLOBIN AND ITS ASSOCIATION WITH 
PULMONARY FUNCTION TESTS: 
The rate of formation of glycation products is proportional to the 
concentration of blood sugar.(85)So glycemic control must have some correlation 
with the pulmonary function tests in diabetic individuals. Glycemic control in a 
diabetic individual can be assessed by measuring the level of glycosylated 
hemoglobin (HbA1c). HbA1c value serves as an indicator of control of blood 
sugar over a short term period of one to three months. 
A person with HbA1c <7% is said to be under control and those with 
HbA1c more than 7% is said to have poor control of blood sugar.(86)If HbA1c is 
more than 7% then the rate of glycation of tissue proteins will be on higher side. 
Thus glycation of collagen and elastin can affect the lungs and will cause decrease 
in the values of pulmonary function tests. 
Increase in glycosylated hemoglobin can interfere with diffusion capacity 
of the lungs due to poor affinity of glycosylated hemoglobin to carbonmonoxide.  
REVIEW: 
A study conducted by Sanjeev Verma et al.(87) suggests that non-enzymatic 
glycosylation of collagen and elastin in lungs due to hyperglycemia can affect the 
mechanical function of lungs which can manifest as altered lung volumes. The 
reason behind it may be microangiopathy. As pulmonary interstitium, vessels, 
major bronchi are rich in collagen, lung functions are affected in diabetes. Though 
these changes are common in old age the severity of this condition is more 
pronounced in diabetes. The alteration in scleroproteins is reversible to begin 
with, so if blood glucose levels are maintained within normal range the 
progression of this condition can be delayed. 
In this study pulmonary functions were compared between type I, typeII diabetics 
and normal controls. PFT was done using computerized Medspiror. Apart from 
this a comparison was done between anthropometric variables like height, weight 
as well as body surface area in diabetic individuals that includes both males and 
females. The study found no significant difference between male and female 
subjects. 
 
A study by Sreeja et al.(88) found no significant difference in 
anthropometric variables between male with diabetes and normal control. This 
study was done to interpret the pulmonary function in diabetics on oral 
hypoglycemic and those on insulin with normal subjects.PFT was done with 
Pesomedicare smart Spirometer .The study found reduction in FEV1 and FVC% 
in diabetics on both oral hypoglycemics as well as insulin therapy as compared 
with the normal subjects. 
The study shows that there is reduction in FEF 25-75%(forced expiratory flow 
rate)  in diabetics who were on oral hypoglycemics as compared to controls. 
A study by Lange et al. was done to interpret the effect of plasma glucose 
and diabetes on lung functions especially FVC and FEV1.Pulmonary function test 
was carried out with Monaghan N 403 spirometer. The study showed reduction in 
FVC and FEV1 values in both type I and type II diabetics but the value was 
reduced more in diabetics on insulin compared to those not on insulin .(89) 
A study by Schnapf et al. showed reduction in lung volumes as well as in 
mobility of joints in type II diabetics(90)This proves that non enzymatic 
glycosylation of connective tissue(collagen) occurs in people with high plasma 
glucose(91). 
One of the confounding factors that can affect the values of FEV1 and FVC is 
obesity. Most of the type II diabetics are obese (92). But the  study done by Lange P 
et al. shows that pulmonary functions were reduced in type I diabetics as 
compared to type II and BMI in type I diabetics is lower than that of the controls. 
The study concludes that there is significant reduction in lung function in 
diabetics treated on insulin than those on oral treatment and diet. 
A study by Davis et al. (93) has suggested that chronic complications of type 
II diabetes will include limitation of air flow and also reduction in lung volumes. 
The study proved that vital capacity,FVC,FVE1and peak expiratory flow rates are 
reduced in type II diabetics. 
A study by Anasuma et al. (94). shows considerable reduction in the forced 
vital capacity in Japanese diabetic patients in comparison to controls 
A study by Ramirez et al. showed considerable difference in FVC in 
diabetics on oral hypoglycemics and those on insulin treatment(95). 
A study by Femognari et al. showed that diabetics suffer from restrictive 
pattern of lung function due to reduction in FVC and FEV1 and normal 
FEV1/FVC.(96)  
Another study by Nakajima et al. (97). showed restrictive pattern and not 
obstructive pattern of pulmonary function that may be associated with metabolic 
syndrome. In this study metabolic factors and percentage of predicted forced vital 
capacity (%PFVC) were compared. %PFVC is an indicator of lung compliance. It 
was found to have correlation with metabolic abnormalities Abnormal lung 
functions were caliberated based on the  lower limit of normal (LLN) which was 
according to American Thoracic society /European Respiratory Society 
guidelines(98).  
Restrictive pattern of lung disease in metabolic syndrome was correlated and 
assosciated with C- reactive protein which is strong indicator of metabolic 
syndrome. In this study  confounding factors such as obesity was taken into 
account since central obesity has impact on lung function. It results in restrictive 
pattern of lung function as expansion of diaphragm is affected due to central 
obesity. Hence waist circumference was also taken into consideration. Cut-off for 
waist circumference was taken as ≥90 cm for men and ≥80 cm for women. Apart 
from this other factors which correlate with metabolic syndrome such as lipid 
profile especially triglyceride level >1.70mmol/L , high density 
lipoprotein<1.05mmol/L , fasting blood glucose ≥ 6.11 mmol/L , blood pressure ≥ 
130/85mmHg were also taken into consideration. 
PFT was done using Autospiro-507 in standing position. % PEFR obtained 
by dividing observed FVC to that of predicted FVC. Air way resistance was 
measured by taking FEV1/FVC ratio. The study shows association between 
restrictive patterns of lung function and metabolic syndrome. (97) 
A study done by Muhammad et al. (99) showed that diabetic subjects also 
had associated increase in triglyceride levels as when compared to normal 
subjects.PFT was done using Med Graphics profiler. In this study apart from 
FVC,FEV1, its ratio and PEFR, slow vital capacity (SVC) was also taken into 
account. The study showed statistically significant relation between diabetes and 
hypertension with a P value <0.001 and also showed high triglyceride levels in 
diabetics, which also had a P value of <0.001.The study shows a reduction in 
FVC,FEV1, in diabetic subjects but no much difference in FEV1/FVC ratio and 
maximum mid expiratory flow (MMEF).The major  limitation of the study was a 
small sample size, then the association between blood sugar control and lung 
function was not correlated, then the diffusing lung capacity was not assessed due 
economic issues. 
A study conducted by Meo et al. (100,101) has showed a relation between 
disease duration and lung function. The lung function was found to be reduced 
with a dose effect relation of duration of diabetes. They found marked reduction 
in FVC,FEV1 and PEF in diabetic subjects as when compared to normal subjects. 
An Indian study showed impairment of diffusion capacity for carbon- 
monoxide in diabetics especially Asian Indians. In this study subjects were 
divided into three groups. 
Group 1: Type 2 diabetics with microvascular complications 
Group 2: Type 2 diabetics without any microvascular complication. 
Group 3: Normal healthy individuals. 
Patients with microangiopathies were selected based on the expert opinion. 
Criteria for diabetic retinopathy: 
       Patients with non proliferative macular edema. 
 
 
 
Criteria for diabetic nepropathy: 
       1. 24 hour urine test was done to detect loss of >300mg of albumin in urine. 
       2.  Criatinine clearance was calculated. 
Criteria for diabetic neuropathy:  
        1. Loss of >2 stretch reflexes in legs. 
        2. Decreased tactile sensations, kinesthesia, Pallesthesia 
Criteria for microangiopathy: 
       1. History of myocardial infarction or cerebrovascular accidents.  
       2. Changes in ECG, ECHO along with clinical examination concluded 
cardiovascular problems. 
Criteria for Peripheral neuropathy: 
1. Loss of at least two peripheral pulses. 
2. Chronic ulcers of foot . 
The study concludes that diffusing capacity of carbon monoxide was found to be 
markedly reduced in group one individuals and the parameters like FVC,FEV1, 
PEFR,MIP,MEP were comparable with other groups(102) .The results of 
spirometry was interpreted based on the guidelines given by the American 
thoracic society. The major limitation of this study was a small sample size. 
Swathi et al. (103) showed that restrictive pattern of lung dysfunction is 
attributed to connective tissue glycosylation, decrease in elastic recoil of lungs 
and inflammatory changes. But the study has shown no association between lung 
pathology and glycemic status or duration of disease. The study says that 
pulmonary complication in diabetes has been poorly documented with conflicting 
results. There occurs microangiopathy of pulmonary capillary network. However, 
due to its large reserve, the loss of microvascular bed can be overcome without 
developing any difficulty in breathing. Thus, the condition remains sub-clinical. 
 Many studies have suggested the following pulmonary changes in a 
diabetic: 
 Decreased lung volume 
 Poor elastic recoil 
 Poor performance of respiratory muscle(104,105) 
 Chronic low grade inflammation 
 Reduction in diffusion capacity for carbonmonoxide(106) 
 Autonomic neuropathy of respiratory muscle(107) 
Thus in a diabetics the lung function will deteriorate leading to loss of 
pulmonary reserve. The study shows significant reduction in FVC and FEV1 but 
no change in their ratio(103) Similar reports have been shown in other studies(108-
111).PFT was done using Helios 702 spirometer.The study found that except for 
ratio of FEV1 to FVC all others were reduced and the study says that the 
association between FVC , FEV1, duration of diabetes and glycosylated 
hemoglobin is statistically insignificant as P value was >0.05(102).There is marked 
reduction in the vital capacity in diabetics and they were found to have restrictive 
of lung function (112,113) 
Uchida et al. showed decreased diffusion capacity of lungs in diabetics 
with a defect in perfusion on ventilation scintigrams(114). 
A study conducted in western Australia by Davis, et al.(111) showed that 
VC, FVC, FEV1, and PEFR were decreased in diabetic subjects that is  between 
1.1% and  of 3.1% predicted values .Ehrlich et al. (115) showed that type 2 diabetics 
are prone to develop asthma, fibrosis ,COPD,pneumonia 
A study by Benbassat(116) showed no reduction in lung functions in 
diabetics except that the ratio of residual volume to total lung capacity was 
increased in non insulin dependent diabetes patients when compared to insulin 
dependent diabetics. The study states that Dlco was not affected in those with 
microangiopathic changes when it was corrected for alveolar volume.  
A study by Fawn Yeh et al.(117,118) says that in Asian Indians with metabolic 
syndrome or diabetes mellitus there is marked reduction in pulmonary functions. 
The study suggests that these people develop reduced lung function even prior to 
development of metabolic syndromes due to the adverse effects of obesity. The 
reason behind it is attributed to inflammation which results due to obesity of this 
arti. Diabetes care). The study showed that the percentage predicted values of 
forced vital capacity and forced expiratory volume at 1st second  both were lower 
in participants with metabolic disorder with a p value of < 0.0001. 
The study has divided the subjects into three groups : 
Normal, those with metabolic syndrome, those with diabetes based on the 
concentration of inflammatory markers. As the concentration of inflammatory 
markers raised the percentage predicted values of pulmonary function tests 
reduced. The mechanism behind reduced lung function and metabolic syndrome 
might be attributed to obesity and inflammation resulting from it.(119)The 
limitation of the study is that it has not provided any data for the inflammatory 
markers. 
A study conducted by Mahmoud M suggests that abundant connective 
tissue in lungs can make it a target site for damage in diabetic patients. In this the 
diabetic group was subdivided into two groups that is with those having HbA1c < 
7(group II A) and the other group with HbA1c >7(group II B) and the group I 
were controls. Then comparison between pulmonary functions of the control and 
diabetic group was done which showed a significant difference in FEV1, 
FEV1/FVC, FEF 25-75% with a p value <0.05. But the difference was not 
significant for MVV. Comparison between group I and group IIA showed 
reduction in all PFTs’ except FEF25-75 and MVV.Then comparison between 
group I and II B, between group II A and II B shows significant reduction in all 
parameters.Thus the study says that lung function is markedly reduced in diabetics 
when compared to normoglycemics.The limitation of this study is that it has not 
mentioned any criteria based how the diabetics were divided into those under 
control based on HbA1c values.(120) 
A study done by Yamini et al. (121)showed obstructive, restrictive as well as 
mixed pattern of lung dysfunction in diabetic individuals. In this study 
comparison was done between males and females also. This study includes 25 
healthy and 25 diabetic subjects.  
Of this:  
1.All females showed FVC < 80% of predicted values but among males 
only 48% showed FVC < 80%. 
2.About 33% of women showed FEV1/FVC <70% where as 61% of males 
showed < 70%. 
3. Thus altogether 54% of males showed obstructive pattern as indicated by 
FEV1/FVC < 70% and 31% showed restrictive pattern. 
4. 67% of women had restrictive pattern. 
5. Mixed pattern was seen in 33% women and one male. 
Totally among diabetics 48% showed restrictive pattern and 28% showed 
obstructive pattern 20% had mixed pattern. The limitation of the study is that it 
did not mention about BMI which is an important confounding factor.  
 
 
 
 CONSEQUENCES OF REDUCED PULMONARY FUNCTIONS IN 
DIABETIC PATIENTS: 
 Studies have reported an association between reduced lung function and 
death. In diabetic subjects 10% fall in FEV1 was linked to 12% increase in 
mortality rate.(131)  
 
 The reduction in pulmonary function can reduce the threshold for clinical 
manifestations of lung diseases. Diabetic patients with reduced lung 
functions who develop pneumonia are more prone for developing 
complications at an early stage and the mortality rate is also high.(122) 
 
 As collagen and elastin is widely distributed in the muscles, parenchyma of 
lungs and pleura, most part of the respiratory apparatus seems to be 
affected due to non-enzymatic glycosylation. This leads to increase in 
stiffness of lungs. Increase in stiffness can cause poor negative pressure 
pump. The compliance of lungs ultimately decreases. This leads to 
restrictive abnormality.Initially the patient may not appreciate the 
weakness of respiratory muscles. This may be because the workload during 
normal tidal breathing is put on the diaphragm than other respiratory 
muscles. But in due course of time these muscles will lose force generating 
ability. This in turn will increase the susceptibility of these people to 
develop obstructive parameters. This depends on their sensitivity to various 
infections and pollutions. (70)  
 As diabetic subjects are immunosuppresed, they develop defects in 
neutrophil functions. The process of phagocytosis, chemotaxis and 
bactericidal activities will be impaired in such subjects due to 
hyperglycemia. Hence these people are prone for developing infections. 
 
 Apart from this the lung functions are deteriorated in diabetic subjects. 
This will add on to the risk of hospitalization in these subjects due to 
infections like pneumonia(123)Diabetic subjects with poor lung function are 
prone to develop myocardial infarction.(124) 
 MECHANISM: 
Thickening of basement membrane of alveoli and pulmonary capillaries 
due to glycosylation can cause poor gas exchange across the respiratory 
membrane. This can ultimately lead to poor oxygenation of blood. In a 
person with already compromised coronary circulation, this type of 
pulmonary dysfunction can lead on to myocardial ischemia. 
A study by Tibbilin et al. showed that in those with reduced peak 
expiratory flow rate, the proportion of mortality from coronary heart disease was 
more among male population in Sweden and Goteberg.(124) 
Apart from this when a diabetic person with poor pulmonary function is 
taken for coronary artery bypass surgery, then his poor ventilatory function would 
interfere with weaning from ventilation. 
 The person will be prone to develop dyspnea owing to poor mechanical 
function of lungs, due to glycosylation of the scleroproteins. 
DECREASED LUNG FUNCTION – A MARKER OF 
CARDIOVASCULAR DISEASE: 
It is a known fact that failure of ventricles can lead to engorgement of lung 
vasculature and can cause edema of the interstitium. This will cause a drastic fall 
in the compliance of the lungs and will alter the lung volumes. 
This reduced lung function acts as a marker for heart disease and studies 
have suggested that lung function should be carried out to predict the prognostic 
significance of ventricular arrhythmia. 
This is because the increased rate of death and myocardial infarction 
which was associated with arrhythmia was confined to males with low 
percentage predicted values of FEV1 and low value of FEV/VC ratio. 
 
 
 
 
 
 
 
MATERIALS AND METHODOLOGY 
SETTING: 
PLACE OF STUDY: 
This case-control study was done in the Department of respiratory medicine, 
Department of Biochemistry at PSG Institute of Medical Sciences And 
Research Coimbatore, Tamilnadu, India. 
The study was approved by the institutional ethics committee. 
STUDY DESIGN: 
This is a case control study. Patients with diabetes mellitus were selected 
for studying the abnormalities in pulmonary function and their pulmonary 
function test findings were compared with age and body mass index (BMI) 
matched controls. 
The cases were those with uncontrolled blood sugar level within the age 
group of 30 – 60 years. The cases were selected from the out-patient department 
(OPD) of Endocrinology, provided they fulfilled the inclusion criteria. Then the 
cases and controls were subjected to pulmonary function tests. 
 
 
 
 
TIME FRAME: 
The study was conducted for one year that is from 1st May 2015 to 31st 
May 2016.  
INCLUSION CRITERIA: 
 Thirty diabetic subjects, whose fasting blood glucose was ≥ 126 mg/dl, two 
hour post prandial blood glucose was ≥ 200mg and HbA1c ≥ 6.5g% 
according to current WHO recommendations for the diagnostic criteria for 
diabetes and intermediate hyperglycemia(19) were enrolled in the study as 
cases. 
 Participants were both men and women of age 30 – 60 years were included 
in the study. 
 Thirty age and BMI matched normoglycemic healthy adults, with no 
clinical evidence of chronic illness or medication were enrolled in   the 
control group. 
EXCLUSION CRITERIA: 
Patients with clinical evidence of any chronic respiratory illness like: 
 Asthma 
  Chronic obstructive pulmonary disease 
 Tuberculosis 
  
Patients with history of: 
 Smoking 
  occupational diseases 
 Cardiac illness 
 Connective tissue diseases 
 Musculoskeletal disorders 
Patients contraindicated for spirometry: 
Absolute contraindications: 
 Severe acute airflow limitation depicted by FEV1 <50% of predicted.  
 History of myocardial infarction or cerebrovascular accident in last 3 
months. 
 Uncontrolled hypertension: systolic blood pressure ≥200 mm Hg or 
diastolic pressure ≥120 mmHg. 
 Known case of aortic aneurysm 
Relative contraindications 
 Moderate airflow limitation: FEV1 <60% of predicted or <1.5 litres.  
 Inability to perform spirometry of acceptable quality. 
 Pregnancy, nursing mothers. 
                                   
  
METHODOLOGY: 
Informed written consent was obtained from all the participants before initiation 
of the study. 
Detailed history of every participant was taken- regarding: 
 Recent use of any anti diabetic medications. 
 History of their behavioral habits such as smoking. Then all the smokers 
were excluded from the study. 
 History of any acute or chronic illness was elicited to exclude them from 
the study provided they had a positive history. 
LABORATORY COLLECTION: 
BLOOD GLUCOSE ESTIMATION: 
For fasting blood glucose measurement, about 2ml of blood sample was 
collected from the individual subjects after overnight fasting by 
venipuncture with the help of an evacuated tube system containing EDTA, 
at 8 a.m. in the morning.  
Then the subjects were asked to take their normal diet (breakfast) and 
blood was collected for estimation of post prandial blood glucose two 
hours after food intake.  
HbA1c was also measured from the blood collected for post prandial blood 
glucose estimation.  
All blood samples were stored at 2 - 8º C after collection. Analysis of 
fasting blood glucose and post prandial blood glucose was done using 
COBAS INTEGRA 400/400 plus analyzer using glucose Hexokinase 
Gen.3(GLUC3) method. HbA1c  was analysed using Bio-Rad laboratories, 
D-10 HbA1c version 220-0101 using Immuno-inhibition method. 
BODY MASS INDEX:  
Height and weight of all the participants were measured. 
 Standing height was measured by asking the subject to stand bare foot with 
both the foot together against measuring instrument in centimeters. 
 Weight was measured with weighing machine in light weight garments 
without foot wears in kg.  
Then BMI was calculated for all the participants 
  BMI was calculated using formula: 
           Weight in kg / (Height in meter) ². 
  
SPIROMETRY: 
The instrument used for measuring lung function was Pesomedicare smart 
spirometer. This is a personal computer based USB spirometer. This gives a 
precise value for spirometric measurement. 
 
 
 
 
The instrument works on modern electronics, which fulfills all the requirements 
and guidelines of American Thoracic society (ATS) and European Respiratory 
society (ERS). 
 
Features of software installed: 
 GLI 2012, actual predicted. 
This covers different age, multiple ethinic reference values for spirometry. 
A set of predicted values for age, height and sex were derived using 
prediction equations. New regression equations were derived based on 
these values. 
 SQL Data base: This data base makes sure that the datas are stored with   
high security. This uses applications that allow multiple user networks. 
 This instrument can be upgraded any time. 
 Back up facility is available, which is automated. 
 The result can be obtained in a printed format. 
 Linear flow sensor 
 
This instrument makes use of complete linear flow sensor. The sensor is based on 
pneumotachograph . This helps to carry out the spirometric tests with high 
precision. The sensor are available with different orifice and negligible dead 
space. The measurements are not affected by humidity. 
The system uses standard USB 2.0 interphase. 
Pre-test advice to the participants: 
All the participants were asked to: 
1. Avoid heavy meal prior to the test. 
2. Avoid strenuous exercise before the test. 
3. Avoid tight clothing during the procedure.  
The apparatus was properly caliberated. The operating technique of the 
instrument was based on its manual and the guidelines provided by The 
American Thoracic Society.(20) 
 Then all the participants were given a prior explanation regarding the 
maneuver. A demo was shown to them. The test was carried out by a well 
trained personnel. 
 The test was performed in the sitting posture with the participants’ nose 
closed with a soft nose clip. 
  All the participants were asked to perform the test three times with a period  
of fifteen minutes rest in between. 
 While measuring forced vital capacity the subject was asked to give a 
maximum effort at the beginning of each blow. The subject was 
encouraged to blow out for at least six seconds and stop when the volume 
does not change for one second. 
 Then the difference between the two largest forced vital capacity and 
forced expiratory volume at first second were  analyzed and was found to 
be within 200ml. 
 Best of the three measurements was taken into account. 
 The highest value of forced vital capacity and forced expiratory volume at 
first second was used to calculate their ratio. The ratio expressed was as 
percentage of FVC. 
 The parameters used for analysis were: 
 Forced vital capacity(FVC) 
 Forced expiratory volume at first second(FEV1) 
 FEV1/FVC 
 FEF25-75 
 Peak expiratory flow rate(PEFR)The percentage predicted values of the 
above parameters were used for analysis purpose. 
 For the FEV1/FVC, absolute ratio was taken. 
 
STATISTICAL ANALYSIS: 
 Statistical analysis was done using IBM SPSS statistics software 
(Statistical package for the social science version 19). 
 Student  't'  test was applied to compare the means of quantitative datas’ 
like FEV1/FVC, FVC, FEV1, FEF25-75, PEFR.  
 
 All values were expressed as mean ± SD (Standard deviation). The "p" 
values were interpreted as : 
(i)  p > 0.05 was considered not significant. 
(ii) p < 0.05 was considered statistically significant. 
 Correlation between pulmonary function test parameters like FEV1/FVC, 
FVC, FEV1, FEF25-75, PEFR with HbA1c and Body-Mass Index among 
the diabetics were analyzed by using Pearson correlation analysis. 
 
  
RESULTS 
Table 1: 
Table 1 shows the physical parameters of the diabetic subjects as well as 
the normal healthy controls. 
 
Both the groups were matched for age and body mass index. That is there 
was no statistical difference between the two groups as the “p” value was > 0.05. 
 
The mean value of age for normal healthy controls was 42.63 ± 5.06 and 
for diabetic individuals it was 44.23 ± 5.96. Both the groups were matched for 
age. There was no statistical difference for the mean age for both the groups as the 
“p” value was 0.267 which was statistically not significant. 
 
The mean value of body mass index for normal healthy controls was 26.70 
± 3.95 and for diabetic individuals it was 26.74 ± 4.18. Both the groups were 
matched for the body mass index. There was no statistical difference for the mean 
of body mass index for both the groups as the “p” value was 0.965 which was 
statistically insignificant. 
 
 
 
Table 2: 
Table 2 shows the comparison of pulmonary function tests between 
diabetic subjects and normal healthy controls.  
 
The mean of FEV1/FVC ratio for normal healthy individuals was 82.92 ± 
4.81 and for the diabetic subjects it was 83.67 ± 5.96. There was no statistical 
difference between the two groups for the ratio of FEV1 to FVC as the “p” value 
was 0.597.  
 
The mean value of FVC for normal healthy controls was 99.90 ± 15.85 and 
for diabetic subjects it was 81.83 ± 18.11. There was statistically significant 
difference for the mean of forced vital capacity between the two groups as the “p” 
value was 0.000.  
 
The mean value of FEV1 for normal healthy controls was 91.53 ± 10.60 
and for diabetic subjects it was 77.03 ± 13.81. The difference was statistically 
significant as the “p” was 0.000. 
 
The mean value of PEFR for controls was 95.77 ± 15.54 and for the 
diabetic subjects it was 85.57 ± 18.69. There was statistically significant 
difference between the mean values of PEFR between the two groups, as the “p” 
value was 0.025.  
The mean value of FEF25-75 % for normal healthy controls was 74.83 ± 
20.36 and for diabetic individuals it was 66.90 ± 24.5. The difference was not 
statistically significant as the “p” value was 0.179.   
 
This study shows that the pulmonary function parameters like FVC, FEV1 
and PEFR are reduced in participants with type 2 diabetes as when compared to 
normal healthy participants.  
 
The mean of both FEV1/FVC ratio and FEF25-75%   between the normal 
healthy controls and diabetic individuals was not statistically significant as their 
“p” value was greater than 0.05. 
  
  
Table 3 : 
Table 3 shows comparison of pulmonary function tests among diabetic 
subjects with HbA1c <7 and HbA1c > 7. 
The 30 diabetic subjects were divided into two groups: 
Group 1 = Diabetic subjects with HbA1c < 7 g% 
Group 2 = Diabetic subjects with HbA1c > 7 g% 
The mean of FEV1/FVC in diabetic subjects with HbA1c < 7 g% was 82.92 
± 5.12 and in those with HbA1c > 7 g%, it was 84.10 ± 6.49. But the difference of 
the mean values between the two groups was not statistically significant as the “p” 
value was 0.611. 
 
The mean value of FVC in diabetic individuals with HbA1c < 7 g% was 
88.64 ± 21.50 and for those with HbA1c >7g% was 77.89 ± 15.07. This difference 
was also not statistically significant as the “p” value was 0 .119. 
 
The mean value of FEV1 for diabetic individuals with HbA1c < 7 g % was 
80.91 ± 14.21 and for those with HbA1c >7g% was 74.79 ± 13.43. This also 
showed no statistical difference between the two groups as the “p” value was 
0.249.  
The mean value of FEF25-75% for diabetic individuals with HbA1c < 7 g%  
was 68.18 ± 22.63 and for those with HbA1c >7g%, it was66.16 ± 26.20. This was 
also not statistically significant as the “p” value was 0.214. 
 
The mean value of PEFR in diabetic subjects with HbA1c < 7g % was 
91.45 ± 12.04 and for those with HbA1c > 7g%, it was 82.16 ± 21.19.  
 
Thus the various parameters of pulmonary function tests showed no 
significant difference between the diabetic subjects with HbA1c < 7 g% and 
HbA1c > 7 g%.  
  
Table 4 : 
Table 4 shows the Pearson correlation of pulmonary function tests and 
glycosylated hemoglobin among diabetic subjects. 
Pearson correlation (r2) for FEV1/FVC and HbA1c was 0.307 among 
diabetic subjects. This showed no correlation as the “p” value was 0.09. 
Pearson correlation (r2) for FVC and HbA1c was -0.202 among diabetic 
subjects. This showed no correlation as the “p” value was 0.284. 
 Pearson correlation (r2) for FEV1 and HbA1c was -0.011 among diabetic 
subjects. This showed no correlation as the “p” value was 0.954.  
Pearson correlation (r2) for FEF25-75 % and HbA1c was .136 among diabetic 
subjects. This showed no correlation as the “p” value was 0.473. 
 Pearson correlation (r2) for PEFR and HbA1c was .023 among diabetic 
subjects. This showed no correlation as the “p” value was 0.904. 
There was a slight negative correlation between FVC, FEV1 and HbA1c. 
But this was not statistically significant. 
  
Table 5 : 
Table 5 shows Pearson correlation between pulmonary function tests and 
body mass index among participants: 
 Pearson correlation (r2) for FEV1/FVC and BMI among the participants 
was 0.114. This showed no correlation as the “p” value was .385.  
 Pearson correlation (r2) for FVC and BMI among the participants was -
0.041. This showed no correlation as the “p” value was 0.756. 
Pearson correlation (r2) for FEV1 and BMI among the participants was -
0.019. This showed no correlation as the “p” value was 0.884.  
Pearson correlation (r2) for FEF25-75 % and BMI among all the participants 
was 0.016. This showed no correlation as the “p” value was 0.905. 
  Pearson correlation (r2) for PEFR and BMI among all the participants was 
0.017. This showed no correlation as the “p” value was 0.899. 
There was a slight negative correlation between FVC, FEV1 and BMI, but 
this was again not statistically significant.  
 
 
 
 
Table 6 : 
Table 6 shows the correlation between pulmonary function tests and body 
mass index among diabetic subjects. 
This was  done to confirm whether the body mass index had any 
correlation with pulmonary function tests among the diabetic individuals whose 
lung function was already compromised. 
Among diabetic subjects the Pearson correlation for FEV1/FVC and BMI 
was 0.259 with a “p” value of 0.167. This correlation showed no significance. 
Pearson correlation for FVC was -0.077 with a “p” value of 0.688. 
Pearson correlation for FEV1 was -0.018 with a p value of 0.927. 
Pearson correlation for FEF25-75 % was 0.106 with a “p” value of 0.578. 
 Pearson correlation for PEFR was 0.098 with a “p” value of 0.606. 
This showed a slight negative correlation between FVC, FEV1 and BMI 
among the diabetic subjects. But this correlation was not statistically significant. 
 
 
 
 
 
Table 7 : 
Table 7 shows comparison of pulmonary function tests between 
participants with BMI < 25 and BMI > 25 among diabetic subjects: 
Participants were categorized into two groups: 
Group 1: BMI < 25 
Group 2: BMI > 25 
The mean values for the various parameters for both the groups were: 
FEV1/FVC for those with BMI<25 among the diabetic individuals was 
83.61 ± 5.23 and for those with BMI >25 was 83.70 ± 6.37. This was not 
statistically significant as the “p” value was 0.971. 
FVC for those with BMI < 25 among the diabetic individuals was 76.11 ± 
12.11 and for those with BMI >25 was 84.28 ± 19.90. This was also not 
statistically significant as the “p” value was 0.265. 
FEV1 for those with BMI < 25 among the diabetic individuals was 74.33 ± 
12.83 and for those with BMI >25 was 78.19 ± 14.35. This difference was not 
statistically significant as the “p” value was 0.493. 
FEF25-75 % for those with BMI < 25 among the diabetic individuals was 
60.33 ± 17.93 and for those with BMI >25 was 69.71 ± 26.81. This showed no 
statistical significance as the “p” value was 0.347. 
PEFR for those with BMI < 25 among the diabetic individuals was 85.33 ± 
18.40 and for those with BMI >25 was 85.66 ± 19.26. This also showed no 
statistical significance as the “p” value was 0.965. 
This study showed no significant difference in the mean values of pulmonary 
function tests in both groups. 
  
TABLE 1: 
PHYSICAL CHARACTERISTICS OF PARTICIPANTS 
Parameters 
Controls, 
(n=60) 
Mean ± SD 
Patients with 
Dm (n=60) 
Mean ± SD 
“P” VALUE Significance 
Age (Years) 42.63 ± 5.06 44.23  ± 5.96 0.267 NS(> 0.05) 
BMI (kg/m2) 26.70 ± 3.95 26.74 ± 4.18 0.965 
 
NS(> 0.05) 
 
DM: Diabetes mellitus  
BMI: Body mass index 
P < 0.05 – Significant 
P > 0.05 – Not Significant (NS) 
 
 
 
 
  
TABLE 2: 
 COMPARISON OF PULMONARY FUNTION TESTS BETWEEN 
DIABETIC SUBJECTS AND NORMAL HEALTHY CONTROLS. 
Parameters: 
Percentage 
predicted 
values 
Control 
subjects 
Mean ± SD 
Diabetic 
subjects 
Mean ± SD 
“p”value Significance 
FEV1/FVC 82.92±4.81 83.67±5.96 0.597 NS (>0.05) 
FVC 99.90±15.85 81.83±18.11 0.000 HS (<0.05) * 
FEV1 91.53±10.60 77.03±13.81 0.000 HS (<0.05) * 
FEF25-75% 74.83±20.36 66.90±24.57 0.179 NS (>0.05) 
PEFR 95.77±15.54 85.57±18.69 .025 HS (<0.05) * 
 
FVC – Forced vital capacity 
FEV1 – Forced expiratory volume at first second 
FEF25-75% – Forced expiratory flow rate during first half of FVC 
PEFR – Peak expiratory flow rate  
P < 0.05 – Significant 
P > 0.05 – Not Significant (NS) 
TABLE 3: 
COMPARISON OF PULMONARY FUNCTION TESTS IN 
DIABETIC SUBJECTS WITH HbA1c < 7 and HbA1c > 7. 
Parameters: 
Percentage 
predicted values 
Subjects with 
HbA1c<7 
Mean ± SD 
Subjects with 
Hba1c>7 
Mean ± SD 
“p”value Significance 
FEV1/FVC 82.92±5.12 84.10±6.49 0.611 NS (>0.05) 
FVC 88.64 ±21.50 77.89±15.07 0.119 NS (>0.05) 
FEV1 80.91±14.21 74.79 ±13.43 0.249 NS (>0.05) 
FEF25-75% 68.18±22.63 66.16±26.20 0.214 NS (>0.05) 
PEFR 91.45±12.04 82.16±21.19 1.330 NS (>0.05) 
 
HbA1c – Glycosylated hemoglobin 
P  < 0.05 – Significant 
P > 0.05 – Not Significant (NS) 
 
 
TABLE 4: 
PEARSON CORRELATION OF PULMONARY FUNCTION TESTS 
AND GLYCOSYLATED HEMOGLOBIN AMONG DIABETIC 
SUBJECTS: 
 
r2 – Pearson correlation 
HbA1c – Glycosylated hemoglobin   
P < 0.05 – Significant 
P> 0.05 – Not Significant (NS) 
 
PARAMETERS 
% predicted 
value 
r2 
(Pearson correlation) 
“p” VALUE SIGNIFICANCE 
FEV1/FVC 
with HbA1c 
0.307 0.098 NS (>0.05) 
FVC with 
HbA1c 
-0.202 0.284 NS (>0.05) 
FEV1 with 
HbA1c 
-0.011 0.954 NS (>0.05) 
FEF 25-75 with  
HbA1c 
0.136 0.473 NS (>0.05) 
PEFR with  
HbA1c 
0.023 0.904 NS (>0.05) 
TABLE  : 5 
PEARSON CORRELATION FOR BODY MASS AND INDEX 
PULMONARY FUNCTION TESTS AMONG THE PARTICIPANTS: 
 
P < 0.05 – Significant 
P > 0.05 – Not Significant (NS) 
 
 
 
 
 
 
Parameters 
% predicted 
value 
r2 
(PEARSON 
CORRELATION) 
“p” value Significance 
FEV1/FVC 
with BMI 
0.114 0.385 NS (>0.05) 
FVC with BMI -0.041 0.756 NS (>0.05) 
FEV1 with 
BMI 
-0.019 0.884 NS (>0.05) 
FEF 25-75 with 
BMI 
0.016 0.905 NS (>0.05) 
PEFR with 
BMI 
0.017 0.899 NS (>0.05) 
TABLE : 6 
PEARSON CORRELATION FOR BODY MASS INDEX AND 
PULMONARY FUNCTION TESTS AMONG                       
DIABETIC  INDIVIDUALS: 
 
 
P < 0.05 – Significant 
P > 0.05 – Not Significant (NS) 
 
 
 
 
Parameters 
% predicted 
value 
r2 
(PEARSON 
CORRELATION) 
“p”value Significance 
FEV1/FVC 
with BMI 
0.259 0.167 NS (>0.05) 
FVC with BMI -0.077 0.688 NS (>0.05) 
FEV1 with 
BMI 
-0.018 0.927 NS (>0.05) 
FEF 25-75 with 
BMI 
0.106 0.578 NS (>0.05) 
PEFR with 
BMI 
0.098 0.606 NS (>0.05) 
TABLE 7: 
COMPARISON OF PULMONARY FUNCTION TESTS BETWEEN 
PARTICIPANTS WITH BMI < 25 AND > 25 AMONG DIABETIC 
SUBJECTS: 
PARAMETERS: 
Percentage 
Predicted values 
SUBJECTS 
WITH 
BMI<25 
Mean ± SD 
SUBJECTS 
WITH 
BMI>25 
Mean ± SD 
“p” VALUE SIGNIFICANCE 
FEV1/FVC 83.61±5.23 83.70±6.37 .971 NS (>0.05) 
FVC 76.11 ±12.11 84.28±19.90 .265 NS (>0.05) 
FEV1 74.33±12.83 78.19±14.35 .493 NS (>0.05) 
FEF25-75% 60.33±17.93 69.71±26.81 .347 NS (>0.05) 
PEFR 85.33±18.40 85.66±19.26 .965 NS (>0.05) 
 
P < 0.05 – Significant 
P > 0.05 – Not Significant (NS) 
 
CHART 1: 
COMPARISON OF FEV1/FVC BETWEEN DIABETIC SUBJECTS 
AND NORMAL HEALTHY CONTROLS.  (MEAN & SD) 
 
 FEV1 – Forced expiratory volume at first second.  
FVC – Forced vital capacity  
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CHART 2: 
COMPARISON OF FVC BETWEEN DIABETIC SUBJECTS AND 
NORMAL HEALTHY CONTROLS. 
 
 
FVC – Forced vital capacity  
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CHART 3 : 
COMPARISON OF FEV1 BETWEEN DIABETIC SUBJECTS AND 
NORMAL HEALTHY CONTROLS. 
 
 
 
FEV1 – Forced expiratory volume at first second 
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CHART 4 :  
COMPARISON OF FEF25-75%BETWEEN DIABETIC SUBJECTS 
AND NORMAL HEALTHY CONTROLS. 
 
 
FEF25-75%   -Forced expiratory flow rate at 25-75% of FVC. 
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CHART 5:  
COMPARISON OF PEFR BETWEEN DIABETIC SUBJECTS AND 
NORMAL HEALTHY CONTROLS. 
 
 
 PEFR – Peak expiratory flow rate  
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DISCUSSION 
Lung parenchyma which includes the respiratory bronchioles, alveolar 
ducts, alveoli, blood vessels, interstitium are rich in connective tissue elements 
such as collagen and elastin. 
Though the bronchioles lack cartilages the lungs are able to maintain their 
patency because of the elasticity of its parenchyma. The major determinant of the 
elasticity of the lung parenchyma is elastin fibers. The stretching ability of the 
elastin fibers are about 140% of their length in the relaxed state.(54)The elastin 
fibers with few fibroblast are found in the alveoli of lungs which promotes normal 
exhalation. 
 But collagen which is inelastic, contributes to the architecture and tensile strength 
of the lung. Collagen can stretch only up to 2% of its resting length. 
The elastic connective tissue surrounding the alveoli of lungs gets stretched 
during inhalation. During the process of expiration these fibers recoil to squeeze 
the air out. Thus expiration is a passive process where there is neither need of any 
work to be done nor there is any energy expenditure. This property is due to the 
normal elasticity of the lungs. 
The interstium of lung parenchyma consists mainly of collagen fibers 
which are of mainly type 1 and type 3. Collagen is responsible for the structural 
framework of the alveolar wall that is, it maintains the architecture of alveolar 
wall. 
In diabetic individuals there occurs non-enzymatic glycosylation of 
collagen and elastin, which in turn can affect the ventilator functions. 
In this study the diabetic subjects and the controls were matched for age 
and body mass index. So both the confounding factors were excluded . 
The ventilatory functions in this study which was measured by Pesomedicare  
smart spirometer showed the following data: 
1. Forced vital capacity (FVC):  
Forced vital capacity which is an important component of flow volume loop   
depicts the total volume of air that is exhaled with maximum effort. 
The normal percentage predicted value of FVC is 80-120%.  
This study shows a marked reduction in forced vital capacity in individuals with 
diabetes as when compared to normal healthy controls. 
The reason attributable to this reduction may be due to: 
 Reduced compliance of lungs due to due to non-enzymatic glycosylation of 
collagen and elastin. 
 The other reason must be thickening of the basal lamina of the epithelium in the 
alveoli. 
           This result goes hand in hand with many other studies.  
A cohort study conducted by Davis et al. (72) among the European 
community shows similar decrease in forced vital capacity. The study states that 
the reduced value of forced vital capacity is due to glycation of proteins in 
diabetic individuals which will affect the compliance of lungs. Chronic exposure 
to high glucose level can lead to thickening of alveolar basement membrane. 
These pathologic changes  in diabetic individuals were identified by  the 
histologic changes found in the lung of  diseased. 
A cross sectional study done by Lange P et al. (89) among adults of middle 
age in United states also showed a marked decrease FVC in diabetic subjects. The 
study says that the reduction in FVC among diabetic population is faster as when 
compared to non- diabetic population with a difference of approximately 8%. 
Apart from the non enzymatic glycosylation of proteins of the bronchial tree and 
microangiopathy the study includes another factor. That is, inflammation and  
oxidative stress among the diabetic subjects can affect the efficiency of 
respiratory muscles, which in-turn can affect ventilation.  
A study done by Asanuma et al. (122) among diabetic subjects of Pakistan 
showed marked decrease in FVC. The study says that this one of chronic 
complications of diabetes owing to poor recoiling of lungs as a result of glycation 
of scleroproteins. 
A study by Barrett et al. (123) says that the reduction in FVC among diabetic 
population implies that these effects of hyperglycemia actually develops even 
before the person becomes full blown diabetic suggesting that even the impaired 
glucose tolerance state can lead to structural and functional abnormality of 
structural proteins owing to non enzymatic glycosylation. 
A study by Marvisi M et al. (124) shows that there is reduction in FVC 
among diabetic subjects which is attributable to the fact that hyperglycemic state 
can lead to thickening of basement membrane of alveoli and pulmonary 
capillaries. The study also suggests a decrease in the diffusing capacity of lungs as 
the DLCO value was markedly reduced in diabetic subjects due to thickening of 
basal lamina of pulmonary capillaries.  
  2.   Forced expiratory volume at first second (FEV1):  
It is the amount of air breathed out with maximum effort in the first second. The 
normal percentage predicted value of FVC is 80-120%.  
This study shows a marked reduction in FEV1 among diabetic population as when 
compared to normal healthy controls. 
The reason for marked reduction in FEV1 is attributed to: 
 Poor recoiling of lung tissues due to non-enzymatic glycosylation of the 
scleroproteins collagen and elastin. 
  Thickening of basal lamina of alveolar epithelium.  
This result correlates with the following studies. 
A cohort study conducted by Davis et al. (72) and a study by  Sanjeev sinha et 
al.(102) suggests that the reduction of FEV1 among the diabetic subjects when 
compared to normal healthy controls  is due to poor elastic recoiling of the lungs 
as the visco elastic nature of lung parenchyma is lost as a result of thickening of 
collagen and loss of elastic nature of elastin owing to glycation.  
  3. Peak expiratory flow rate (PEFR): 
The normal value of PEFR is 400-600ml/min.This study shows that in 
diabetic subjects there is marked reduction in the PEFR values as compared to the 
normal subjects. This implies that there is marked fall in the strength of the 
muscles of expiration, which is reflected as fall in force generating capacity of 
these muscles. This may be either due to increased protein catabolism or due to 
poor neuromuscular function of respiratory muscles as a part of diabetic 
neuropathy or change in composition of muscle fibers.  
This result is similar to the study done by Kabitz HJ et al. (125) which states 
that the reduction in peak expiratory flow rate among diabetic subjects is due to 
poor efficiency of muscles of expiration , as  the maximum velocity with which 
air is forced out of lungs depends on the strength of muscles of expiration. This 
may be due to enhanced protein catabolism. 
A study done by Marin P et al. (125) also shows a marked reduction in peak 
expiratory flow rate in diabetic subjects as when compared to normal healthy 
controls. This is attributed to the fact that, in diabetic individuals’ peripheral 
neuropathy can result in reduced neuromuscular function, which can affect the 
muscles of respiration. 
4. FEV1/ FVC :  
In this study the mean of absolute ratio of FEV1 to FVC among diabetics 
were found to be slightly more than that of the normal controls but was not 
statistically significant. 
The increase in the mean value of the ratio suggests that diabetic 
individuals have a restrictive pattern of lung disease. 
This result correlates with certain other studies.  
A study by Barrett et al. (123) says that the increase in FEV1 / FVC that is 
more than 0.70 among diabetic subjects supports the evidence of restriction 
according to the guidelines given by the American thoracic society and 
European respiratory society.  
5. FEF25-75% : 
This exhibits forced expiratory flow somewhere at the middle of forced 
vital capacity. 
This value exhibits the patency of small airways which actually depends on 
the total volume of air exhaled that is forced vital capacity. 
The mean value of forced expiratory flow at 25-75% is roughly reduced in 
diabetic subjects than that of the controls. But this value is not statistically 
significant. This again depends on the mechanical properties of lungs.  
This result is in accordance with the study done by Sodhi C et al.(74)  
The study says that FEF25-75% is said to depend on both the neuromuscular 
factors as well as the mechanical properties of the respiratory system as  FEF25-
75% depicts nothing but the initial part of forced vital capacity.  
According to the guidelines given by the American Thoracic Society 
FEV1/FVC ≥ 70% with markedly reduced value of FVC and FEV1 values suggest 
restrictive type of respiratory impairment.(10)In this study the mean of percentage 
predicted values of forced vital capacity as well as forced expiratory volume at 
first second is markedly reduced in diabetic subjects when compared to normal 
subjects. Hence the diabetic subjects in this study show a restrictive pattern of 
ventilatory impairment. 
Studies have shown low vital capacity and restrictive pattern of respiratory 
impairment among type 2 diabetic subjects.(128,129) 
6.  Comparison of pulmonary functions in diabetic subjects with  
HbA1c < 7g % and    HbA1c > 7g %. 
A study by Van den Borst et al. showed a restrictive pattern of lung 
function among diabetic subjects which was statistically significant. But the 
limitation of the study was that it did not take BMI, HbA1c and smoking into 
consideration. (130)The present study has compared the pulmonary functions with 
the glycemic control. A good indicator for glycemic control is HbA1c value. 
The correlation of HbA1c of diabetic subjects with their pulmonary 
function tests’ showed slightly negative correlation for FVC and FEV1.But this 
was not statistically significant. The slight negative correlation shows that lung 
function is slightly decreased in diabetic subjects as the lung parenchyma which is 
rich in collagen and elastin is prone for non-enzymatic glycosylation due to high 
blood glucose level. This can lead to stiffening of parenchyma, which will 
ultimately affect the lung volumes and capacities.  
The lung parenchyma changes are evident by electron microscopic studies 
of lung tissue of diseased diabetic subjects. It showed thickening of capillary 
endothelium and basement membrane.  
The statictiscal insignificance may be due to the fact that, though HbA1c 
levels are strong indicators of glycemic control, it depicts the glycemic control for 
only a short  duration of 1-3 months. And this short term control in no way can 
explain the effect of long term high plasma glucose level on lung mechanics. 
This correlates with the study done by Lange P et al. (110) This study was 
done in The United nations among the middle aged population. The HbA1c values 
showed a negative correlation with lung functions as high blood glucose will 
affect the mechanical function of lungs. 
7. Correlation of body mass index with pulmonary functions among 
diabetic individuals: 
The correlation between body mass index and pulmonary function tests’ 
among diabetic subjects showed a slight negative correlation for both forced vital 
capacity and forced expiratory volume at first second. But this was not 
statistically significant. This may be attributed to small sample size. 
 
This result goes hand in hand with the study conducted by Jitendra Singh et 
al.(86)which shows that there is no correlation between pulmonary function tests 
and factors like body mass index and gender.  
CONCLUSION 
In diabetic patients following changes are noted in the lung:  
 Non-enzymatic glycosylation of collagen and elastin can lead to increased 
cross link formation between polypeptides of collagen causing stiffening of 
lung parenchyma as well as poor elastic recoiling of lung tissue. This 
causes restrictive pattern of lung dysfunction in these subjects. 
 Microangiopathy not only affects the kidneys, nervous system, and eyes, 
but also damages the alveolar basement membrane. 
 There is more chance for reduced strength of respiratory muscles, owing to 
increased protein catabolism. 
 Next important complication in diabetes is thickening of basement 
membrane of thoracic and phrenic nerves as a part of diabetic neuropathy, 
which can cause demyelination, chromatolysis of their axons and Schwann 
cells. This can also lead to decrease in strength of respiratory muscles. 
Thus spirometry a non-invasive procedure must be added as a part of 
investigation to monitor the effects of diabetes on lungs and also for early 
detection of lung function to prevent any further complication due to poor 
ventilatory function. 
 
 
                                                           
 A good control of blood sugar may decrease the risk of mortality through 
correction of ventilatory functions. 
 In a person with uncontrolled blood sugar level the chance for developing 
respiratory infection is more. Hence it is advisable to immunize them against 
influenza and pnuemoccocus.(135) 
 Studies say that pyridoxamine and aminoguanidine compounds have the 
ability to prevent the formation of advanced glycation end products, in animal 
models.(12) 
Aminoguanidine is an AGE-inhibitor. It helps to prevent various signs of aging 
process. But as it has the ability to prevent or slow down the proteins from cross 
linking, it can be tried in diabetic subjects also.  
Aminoguanidine tends to bind to the sugars and prevent the binding of 
sugars to the lysine group of proteins. Thus aminoguanidine helps to maintain 
and stabilize the glucose metabolism (136). 
1. Stage 3 trial for aminoguanidine is going on at the Alteon Corporation in 
the USA. The main function of aminoquanidine, carnosine, acetyl-α-
carnitine is to prevent cross link formation. 
2. Another important development is ALT-711 (Thiazolium salt). This is 
under 2nd stage of trial. This helps to break the existing links. 
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ANNEXURE – I 
 
PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS FOR CASES 
 
 
 
I, Dr.R.L.Bhavya, am carrying out a study on the topic: Pulmonary Functions In Type 
II Diabetes Patients And its correlation with factors affecting glycemic status  as 
part of my project being carried out under the aegis of the Department of Physiology
   
 
(Applicable to students only): My research guide is: Prof.Nagashree.R. 
 
The justification for this study is:  
 
Though pulmonary dysfunction in TypeII Diabetes patients is well documented in 
literature, yet there is lack of adequate data on Indian population, more so from 
southern India. The present study will attempt to fill the paucity of knowledge in 
Indian scenario. 
 
The objectives of this study are:  
 
Primary Objectives:  
 To assess the pulmonary functions of TypeII Diabetic patients and 
compare it with age and sex matched healthy individuals 
         Secondary Objectives: 
To identify the correlation between lung functions of Diabetic patients and factors 
like  
• Age 
• Sex  
• BMI 
• HbA1c 
 
Sample size: 30 TypeII Diabetic participants and 30 normal study volunteers. 
 
Study volunteers / participants are (specify population group & age group): both sex, 
age matched.  
 
Location:     Endocrinology clinic PSGIMS & R 
We request you to kindly cooperate with us in this study. We propose collect background 
information and other relevant details related to this study. We will be carrying out:  
Initial interview: collecting participants(controls) details through data collection 
tools. The controls and cases will undergo pulmonary function testing, using 
Pesomedicare smart spirometer. Data collected will be stored for a period of fifteen 
years. We will not use the data as part of another study. 
Benefits from this study for the study volunteers? 
 
 To know pulmonary functions of the type II Diabetic patients. 
 If they have abnormal PFT’s they are informed and send to 
pulmonology or respiratory medicine department for further 
evaluation. 
 
Risks involved by participating in this study: NO  
 
 
How the results will be used:  
 To my project study. 
 
If you are uncomfortable in answering any of our questions during the course of the 
interview, you have the right to withdraw from the interview / study at anytime. You 
have the freedom to withdraw from the study at any point of time. Kindly be assured that 
your refusal to participate or withdrawal at any stage, if you so decide, will not result in 
any form of compromise or discrimination in the services offered nor would it attract any 
penalty. You will continue to have access to the regular services offered to a patient. You 
will NOT be paid any remuneration for the time you spend with us for this interview / 
study. The information provided by you will be kept in strict confidence. Under no 
circumstances shall we reveal the identity of the respondent or their families to anyone. 
The information that we collect shall be used for approved research purposes only. You 
will be informed about any significant new findings - including adverse events, if any, – 
whether directly related to you or to other participants of this study, developed during the 
course of this research which may relate to your willingness to continue participation. 
 
Consent: The above information regarding the study, has been read by me/ read to me, 
and has been explained to me by the investigator/s. Having understood the same, I 
hereby give my consent to them to interview me. I am affixing my signature / left thumb 
impression to indicate my consent and willingness to participate in this study (i.e., 
willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
 
Signature of the Interviewer with date:     
 Witness: 
 
 
 
Contact details of PI: Phone: : +91-0422-2570170   Extension No.: 5809.  
                                      PHONE 9715874362 
                                      rlbhavya83@gmail.com 
 
Contact details of IHEC: Phone: +91-0422-2570170  Extension No.: 5818.  
                                             
 
 
ANNEXURE – II 
PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS FOR 
CONTROLS  
 
 
I, Dr.R.L.Bhavya, am carrying out a study on the topic: Pulmonary Functions In 
TypeII Diabetic Patients And its correlation with factors affecting the glycemic 
status  , as part of my project being carried out under the aegis of the Department of 
Physiology   
 
(Applicable to students only): My research guide is: Prof.Nagashree.R. 
 
The justification for this study is:  
 
Though pulmonary dysfunction in Diabetic patients is well documented in 
literature, yet there is lack of adequate data on Indian population, more so from 
southern India. The present study will attempt to fill the paucity of knowledge in 
Indian scenario. 
 
The objectives of this study are:  
 
Primary Objectives:  
 To assess the pulmonary functions of TypeII Diabetic patients and 
compare it with age and sex matched healthy individuals 
         Secondary Objectives: 
To identify the correlation between lung functions of RA patients and factors like  
• Age  
• sex 
• BMI 
• HbA1c 
  
Sample size: 30 TypeII Diabetic participants and 30 normal study volunteers. 
 
Study volunteers / participants are (specify population group & age group): both sex, 
age matched.  
 
Location:     Endocrinology clinic PSGIMS & R 
We request you to kindly cooperate with us in this study. We propose collect background 
information and other relevant details related to this study. We will be carrying out:  
Initial interview : collecting participants(controls) details through data collection 
tools. The controls and cases will undergo pulmonary function testing, 
Pesomedicare smart spirometer. Data collected will be stored for a period of fifteen 
years. We will not use the data as part of another study. 
 
Benefits from this study for the study volunteers? 
 
 To know pulmonary functions of the controls. 
 If they have abnormal PFT’s they are informed and send to 
pulmonology or respiratory medicine department for further 
evaluation. 
 
Risks involved by participating in this study: NO  
 
How the results will be used:  
 To my project study. 
 
If you are uncomfortable in answering any of our questions during the course of the 
interview, you have the right to withdraw from the interview / study at anytime. You 
have the freedom to withdraw from the study at any point of time. Kindly be assured that 
your refusal to participate or withdrawal at any stage, if you so decide, will not result in 
any form of compromise or discrimination in the services offered nor would it attract any 
penalty. You will continue to have access to the regular services offered to a patient. You 
will NOT be paid any remuneration for the time you spend with us for this interview / 
study. The information provided by you will be kept in strict confidence. Under no 
circumstances shall we reveal the identity of the respondent or their families to anyone. 
The information that we collect shall be used for approved research purposes only. You 
will be informed about any significant new findings - including adverse events, if any, – 
whether directly related to you or to other participants of this study, developed during the 
course of this research which may relate to your willingness to continue participation. 
 
Consent: The above information regarding the study, has been read by me/ read to me, 
and has been explained to me by the investigator/s. Having understood the same, I 
hereby give my consent to them to interview me. I am affixing my signature / left thumb 
impression to indicate my consent and willingness to participate in this study (i.e., 
willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
Signature of the Interviewer with date:     
 Witness: 
 
 
Contact details of PI: Phone: +91-0422-2570170  Extension No.: 5809.  
                                      PHONE9715874362 
                                      rlbhavya83@gmail.com 
 
Contact details of IHEC: Phone: +91-0422-2570170  Extension No.: 5818.  
                                             
  
 
  
 
  
 
  
ANNEXURE – IV  
DATA COLLECTION TOOL 
 
NAME  : 
AGE   : 
GENDER  : 
OCCUPATION : 
HEIGHT  : 
WEIGHT  : 
BMI   : 
FAMILY HISTORY  : 
TREATMENT HISTORY : 
ARE YOU ON TREATMENT FOR ANY OTHER CHRONIC DISEASE  
(LIKE HYPERTENSION, ISCHEMIC HEART DISEASE MYCADIAL 
INFARCTION)? 
PERSONAL HISTORY (ALCOHOLIC / SMOKING / TOBACCO CHEWING): 
 
 
SIGNATURE OF PARTICIPANT 
  
 
 
